TY - JOUR
T1 - Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT
AU - Bauer, Sebastian
AU - Corless, Christopher L.
AU - Heinrich, Michael C.
AU - Dirsch, Olaf
AU - Antoch, Gerald
AU - Kanja, Jörg
AU - Seeber, Siegfried
AU - Schütte, Jochen
PY - 2003/3/1
Y1 - 2003/3/1
N2 - More than 90% of gastrointestinal stromal tumors (GISTs) express the receptor tyrosine kinase KIT, and activating mutations of the KIT gene are detectable in the vast majority of these tumors. Imatinib mesylate (formerly STI571) is a potent inhibitor of KIT kinase activity and has been proven to be highly active in patients with unresectable or metastatic GIST expressing immunohistochemically detectable KIT protein. Here we report a patient with metastatic GIST who responded well to imatinib mesylate treatment despite the near absence of KIT expression in two different samples of his tumor. The tumor was morphologically typical for a GIST, stained positively for CD34, and harbored an in-frame deletion (WK 557-558) in KIT exon 11 that is common in GISTs. Our experience with this patient suggests that even GISTs with very low levels of KIT expression may respond to imatinib mesylate therapy.
AB - More than 90% of gastrointestinal stromal tumors (GISTs) express the receptor tyrosine kinase KIT, and activating mutations of the KIT gene are detectable in the vast majority of these tumors. Imatinib mesylate (formerly STI571) is a potent inhibitor of KIT kinase activity and has been proven to be highly active in patients with unresectable or metastatic GIST expressing immunohistochemically detectable KIT protein. Here we report a patient with metastatic GIST who responded well to imatinib mesylate treatment despite the near absence of KIT expression in two different samples of his tumor. The tumor was morphologically typical for a GIST, stained positively for CD34, and harbored an in-frame deletion (WK 557-558) in KIT exon 11 that is common in GISTs. Our experience with this patient suggests that even GISTs with very low levels of KIT expression may respond to imatinib mesylate therapy.
KW - GIST
KW - Gastrointestinal stromal tumor
KW - Imatinib
KW - KIT immunonegativity
UR - http://www.scopus.com/inward/record.url?scp=0344837699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344837699&partnerID=8YFLogxK
U2 - 10.1007/s00280-002-0564-x
DO - 10.1007/s00280-002-0564-x
M3 - Article
C2 - 12655446
AN - SCOPUS:0344837699
SN - 0344-5704
VL - 51
SP - 261
EP - 265
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 3
ER -